UTICORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UTICORT (UTICORT).
Uticort (betamethasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Hepatic metabolism via CYP3A4; metabolites are glucuronidated and excreted renally. |
| Excretion | Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% via enterohepatic circulation. |
| Half-life | Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 6-12 hours in hepatic impairment. |
| Protein binding | 90-95% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-1.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% (first-pass effect); topical: 2-5% (systemic absorption dependent on skin integrity); intravenous: 100%. |
| Onset of Action | Topical: within 2-3 hours; oral: 30-60 minutes; intravenous: within 5 minutes. |
| Duration of Action | Topical: 12-24 hours with once-daily application; oral: 6-12 hours; intravenous: 4-8 hours. |
| Molecular Weight | 476.58 |
Topical: Apply a thin film to affected area twice daily. Maximum 50 g per week. For short-term use only (≤2 weeks).
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for renal impairment. No GFR-based data available. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B/C: Use with caution due to potential for systemic accumulation; limit to small areas and short duration. |
| Pediatric use | Children ≥2 years: Apply sparingly to affected area once or twice daily for ≤2 weeks. Avoid occlusion. Not for diaper dermatitis. |
| Geriatric use | Use with caution due to thinner skin and increased risk of systemic absorption and skin atrophy. Apply sparingly to limited areas for shortest duration possible. |
| 1st trimester | Avoid during first trimester unless potential benefit outweighs risk; associated with increased risk of orofacial clefts (odds ratio ~1.3) based on observational studies. |
| 2nd trimester | Use only if clearly needed; prolonged or high-dose use may lead to fetal adrenal suppression and growth restriction. |
| 3rd trimester | Avoid near term; may cause neonatal adrenal suppression, hypoglycemia, and electrolyte disturbances if given shortly before delivery. |
Clinical note
Comprehensive clinical and safety monograph for UTICORT (UTICORT).
| Placental transfer | Betamethasone crosses the placenta; approximately 30-50% of maternal concentration reaches the fetal circulation. It is metabolized in the placenta to less active forms, but significant fetal exposure occurs. |
| Breastfeeding | Uticort (betamethasone valerate) is excreted into breast milk in small amounts; however, systemic exposure in the infant is likely minimal due to extensive first-pass metabolism. Use only if clearly indicated and at the lowest effective dose for the shortest duration. Monitor infant for signs of adrenal suppression if high doses or prolonged use are required. |
■ FDA Black Box Warning
Do not use for primary treatment of bacterial, fungal, viral, or parasitic infections without appropriate antimicrobial therapy. Systemic absorption may produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with potential for glucocorticosteroid insufficiency after withdrawal.
| Serious Effects |
Hypersensitivity to betamethasone or any component of the formulationSystemic fungal infectionsConcurrent live or attenuated virus vaccinationsUntreated bacterial, viral, or fungal infections at application site
| Precautions | HPA axis suppression, especially with prolonged use or large body surface area application, Cushing's syndrome with systemic absorption, Local adverse reactions including atrophy, striae, and telangiectasia, Increased risk of infection, Allergic contact dermatitis, Ophthalmic effects if used near eyes |
| Food/Dietary | No significant food interactions. Avoid alcohol if experiencing itching or flushing, as it may aggravate some dermatoses. |
Loading safety data…
| Lactation Rating | L2 (Possibly Compatible) |
| Teratogenic Risk | Uticort (betamethasone) is a corticosteroid. First trimester: Increased risk of cleft palate (odds ratio ~3.4). Second/third trimester: Prolonged use may cause fetal adrenal suppression, intrauterine growth restriction (IUGR), and preterm birth. Risk-benefit must be weighed. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (especially in diabetic patients), and signs of infection. Fetal monitoring: serial ultrasound for growth restriction if prolonged use. Neonatal monitoring for adrenal insufficiency if betamethasone administered near term. |
| Fertility Effects | Animal studies show reduced fertility at high doses. Human data limited: may cause menstrual irregularities, but no definitive evidence of impaired fertility. Use with caution in women attempting pregnancy. |
| Clinical Pearls | UTICORT contains betamethasone dipropionate, a potent topical corticosteroid for short-term treatment of corticosteroid-responsive dermatoses. Limit use to 2 weeks to avoid skin atrophy, striae, and HPA axis suppression. Do not use on face, groin, or axillae due to increased risk of atrophy. Occlusion increases systemic absorption – avoid unless directed. Discontinue if infection develops. |
| Patient Advice | Apply a thin layer to the affected area only, avoiding healthy skin. · Use no more than twice daily for up to 2 weeks unless directed otherwise. · Do not cover the area with bandages or wraps unless instructed by your doctor. · Avoid contact with eyes, mouth, or open wounds. · Inform your healthcare provider if no improvement after 2 weeks. · Do not stop abruptly if used long-term; taper as directed to avoid rebound effects. |